[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL3354729T3 - Przeciwciało anty-garp - Google Patents

Przeciwciało anty-garp

Info

Publication number
PL3354729T3
PL3354729T3 PL16848676.9T PL16848676T PL3354729T3 PL 3354729 T3 PL3354729 T3 PL 3354729T3 PL 16848676 T PL16848676 T PL 16848676T PL 3354729 T3 PL3354729 T3 PL 3354729T3
Authority
PL
Poland
Prior art keywords
garp antibody
garp
antibody
Prior art date
Application number
PL16848676.9T
Other languages
English (en)
Inventor
Kazuki Satoh
Kazuki HIRAHARA
Ichiro Watanabe
Masato Amano
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of PL3354729T3 publication Critical patent/PL3354729T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16848676.9T 2015-09-24 2016-09-23 Przeciwciało anty-garp PL3354729T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015187488 2015-09-24
PCT/JP2016/078067 WO2017051888A1 (ja) 2015-09-24 2016-09-23 抗ｇａｒｐ抗体

Publications (1)

Publication Number Publication Date
PL3354729T3 true PL3354729T3 (pl) 2024-05-20

Family

ID=58386752

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16848676.9T PL3354729T3 (pl) 2015-09-24 2016-09-23 Przeciwciało anty-garp

Country Status (29)

Country Link
US (4) US11046780B2 (pl)
EP (3) EP3660051A1 (pl)
JP (4) JP6878283B2 (pl)
KR (1) KR20180053316A (pl)
CN (3) CN110922481A (pl)
AU (3) AU2016325858B2 (pl)
BR (1) BR112018005777A2 (pl)
CA (1) CA2999819A1 (pl)
CO (1) CO2018003542A2 (pl)
DK (1) DK3354729T5 (pl)
ES (1) ES2978126T3 (pl)
FI (1) FI3354729T3 (pl)
HK (1) HK1254310A1 (pl)
HR (1) HRP20240495T1 (pl)
HU (1) HUE066594T2 (pl)
IL (3) IL302932A (pl)
LT (1) LT3354729T (pl)
MX (2) MX2018003594A (pl)
MY (1) MY194586A (pl)
PH (1) PH12018500642A1 (pl)
PL (1) PL3354729T3 (pl)
PT (1) PT3354729T (pl)
RS (1) RS65415B1 (pl)
RU (2) RU2022108079A (pl)
SG (2) SG11201802352VA (pl)
SI (1) SI3354729T1 (pl)
SM (1) SMT202400160T1 (pl)
TW (3) TW202438526A (pl)
WO (1) WO2017051888A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014298373B2 (en) 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
WO2017051888A1 (ja) 2015-09-24 2017-03-30 第一三共株式会社 抗ｇａｒｐ抗体
US11046782B2 (en) * 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019230869A1 (ja) * 2018-05-31 2019-12-05 第一三共株式会社 抗ヒトｔｌｒ７抗体
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
BR112022007632A2 (pt) * 2019-10-25 2022-07-12 Daiichi Sankyo Co Ltd Composição farmacêutica e preparação de kit para tratamento de câncer, e, métodos para tratamento de câncer e de um paciente com câncer
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
BR112023010168A2 (pt) * 2020-12-02 2024-02-06 Shanghai Henlius Biotech Inc Anticorpos anti-garp/tgfbeta e métodos de uso
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CN117425500A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗dll3抗体-药物缀合物
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
US20240327544A1 (en) 2021-07-13 2024-10-03 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AU761587B2 (en) 1998-04-21 2003-06-05 Amgen Research (Munich) Gmbh CD19xCD3 specific polypeptides and uses thereof
EP1914244B1 (en) 1999-04-09 2013-05-29 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
CN1333274A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
RO123525B1 (ro) 2001-11-01 2013-04-30 Uab Research Foundation Metodă in vitro de inducere selectivă a apoptozei sau de inhibare a proliferării celulelor ţintă care exprimă dr5 şi compoziţie pentru inducerea selectivă a apoptozei cuprinzând o combinaţie de anticorpi
JP4589914B2 (ja) 2003-01-07 2010-12-01 シムフォゲン・アクティーゼルスカブ 組換え型ポリクローナルタンパク質の製造方法
WO2006089678A2 (en) 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
US8815526B2 (en) 2005-03-31 2014-08-26 Case Western Reserve University Methods and reagents for identifying/isolating T regulatory (Treg) cells and for treating individuals
EP2001509A1 (en) 2006-04-03 2008-12-17 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
MX2009006879A (es) 2006-12-22 2009-07-03 Schering Corp Anticuerpos contra el cd200r.
WO2009087230A1 (en) 2008-01-11 2009-07-16 Morphosys Ag Display vectors and methods and uses thereof
EP2262530A4 (en) 2008-03-03 2012-12-05 Dyax Corp Metalloproteinase-12 TIE PROTEINS
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2010055950A1 (ja) 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
TWI480050B (zh) 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
EP2430050A1 (en) 2009-05-11 2012-03-21 U3 Pharma GmbH Humanized axl antibodies
EP3284821B1 (en) 2010-03-23 2022-01-05 Precigen, Inc. Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
CN107188963A (zh) 2010-10-29 2017-09-22 第三共株式会社 新的抗dr5抗体
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
RU2668170C2 (ru) * 2011-04-25 2018-09-26 Дайити Санкио Компани, Лимитед Анти-в7-н3-антитело
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
MX2014011826A (es) 2012-03-30 2014-11-21 Daiichi Sankyo Co Ltd Anticuerpo anti-siglec-15 novedoso.
RU2014145001A (ru) 2012-04-09 2016-06-10 Дайити Санкио Компани, Лимитед Антитело против fgfr2
JP2014141434A (ja) * 2013-01-24 2014-08-07 Daiichi Sankyo Co Ltd 抗ｒｏｂｏ４抗体
CA2868074A1 (en) 2012-04-27 2013-10-31 Daiichi Sankyo Company, Limited Anti-robo4 antibody
TWI705073B (zh) * 2012-06-22 2020-09-21 達特茅斯學院基金會 新穎之vista-ig構築體及vista-ig用於治療自體免疫、過敏及發炎病症之用途
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
CA3023553A1 (en) * 2012-11-06 2014-05-15 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
AU2014298373B2 (en) * 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
EP3253796A1 (en) 2015-02-03 2017-12-13 Université Catholique de Louvain Anti-garp protein and uses thereof
WO2017051888A1 (ja) * 2015-09-24 2017-03-30 第一三共株式会社 抗ｇａｒｐ抗体
US11046782B2 (en) * 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination

Also Published As

Publication number Publication date
IL258322B1 (en) 2023-06-01
IL288784B2 (en) 2023-10-01
RU2018114904A3 (pl) 2020-03-03
CN115869398A (zh) 2023-03-31
JP6868739B2 (ja) 2021-05-12
TW201718643A (zh) 2017-06-01
US11046780B2 (en) 2021-06-29
IL288784B1 (en) 2023-06-01
US20180327511A1 (en) 2018-11-15
SG10201912570UA (en) 2020-02-27
US20240360245A1 (en) 2024-10-31
SG11201802352VA (en) 2018-04-27
AU2016325858B2 (en) 2022-05-26
JP2021106617A (ja) 2021-07-29
DK3354729T5 (da) 2024-09-30
EP3354729A1 (en) 2018-08-01
AU2016325858A1 (en) 2018-04-19
AU2020200866A1 (en) 2020-02-27
EP3660051A1 (en) 2020-06-03
RU2018114904A (ru) 2019-10-24
BR112018005777A2 (pt) 2018-10-09
RU2769379C2 (ru) 2022-03-30
SMT202400160T1 (it) 2024-05-14
WO2017051888A1 (ja) 2017-03-30
AU2020200866B2 (en) 2022-06-16
PH12018500642A1 (en) 2018-09-24
JPWO2017051888A1 (ja) 2018-07-12
DK3354729T3 (da) 2024-04-22
ES2978126T3 (es) 2024-09-05
US12006372B2 (en) 2024-06-11
RS65415B1 (sr) 2024-05-31
US10550198B2 (en) 2020-02-04
FI3354729T3 (fi) 2024-04-23
EP3354729B1 (en) 2024-02-14
IL258322B2 (en) 2023-10-01
KR20180053316A (ko) 2018-05-21
CO2018003542A2 (es) 2018-07-10
MX2018003594A (es) 2018-06-15
TWI836305B (zh) 2024-03-21
MX2023003470A (es) 2023-04-19
US20220010026A1 (en) 2022-01-13
CA2999819A1 (en) 2017-03-30
LT3354729T (lt) 2024-04-25
CN110922481A (zh) 2020-03-27
MY194586A (en) 2022-12-05
HUE066594T2 (hu) 2024-08-28
JP2022169801A (ja) 2022-11-09
TW202438526A (zh) 2024-10-01
CN108026521A (zh) 2018-05-11
IL302932A (en) 2023-07-01
AU2022231706A1 (en) 2022-10-06
TW202227501A (zh) 2022-07-16
PT3354729T (pt) 2024-04-11
IL288784A (en) 2022-02-01
JP6878283B2 (ja) 2021-05-26
EP4349997A2 (en) 2024-04-10
HRP20240495T1 (hr) 2024-07-05
HK1254310A1 (zh) 2019-07-19
JP7137657B2 (ja) 2022-09-14
IL258322A (en) 2018-05-31
CN108026521B (zh) 2022-12-06
EP4349997A3 (en) 2024-07-10
US20180258184A1 (en) 2018-09-13
JP2020202875A (ja) 2020-12-24
RU2022108079A (ru) 2022-04-08
SI3354729T1 (sl) 2024-05-31
EP3354729A4 (en) 2019-06-12
TWI751979B (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
HK1254836A1 (zh) 抗-ror1抗體
HK1256116A1 (zh) 抗lag-3抗體
HK1253507A1 (zh) 抗 ror1 抗體
HK1254310A1 (zh) 抗garp抗體
IL253633A0 (en) Anti-transthyretin antibodies
GB201521393D0 (en) Antibodies
GB201521391D0 (en) Antibodies
HK1246804A1 (zh) Tau結合抗體
GB201521382D0 (en) Antibodies
IL256099A (en) antibody
HUE059592T2 (hu) Anti-transztiretin antitestek
GB201508180D0 (en) Antibodies
IL268889A (en) Anti-EPHA4 antibody
GB201515351D0 (en) Antibody
GB201600871D0 (en) Antibody
LT3336185T (lt) Antikūnas
IL257368A (en) antibody
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
GB201513447D0 (en) Antibody
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies